Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
PPD downgraded to Neutral from Overweight at JPMorgan » 09:34
04/28/21
04/28
09:34
04/28/21
09:34
PPD

PPD

$46.34 /

+0.12 (+0.26%)

, TMO

Thermo Fisher

$490.36 /

-3.765 (-0.76%)

JPMorgan analyst Tycho…

JPMorgan analyst Tycho Peterson downgraded PPD (PPD) to Neutral from Overweight with a $48 price target citing the pending takeover by Thermo Fisher (TMO).

ShowHide Related Items >><<
TMO Thermo Fisher
$490.36 /

-3.765 (-0.76%)

PPD PPD
$46.34 /

+0.12 (+0.26%)

PPD PPD
$46.34 /

+0.12 (+0.26%)

04/20/21 Jefferies
PPD downgraded to Hold from Buy at Jefferies
04/19/21
Fly Intel: Top five analyst downgrades
04/19/21 Citi
PPD downgraded to Neutral from Buy at Citi
04/19/21 Mizuho
PPD downgraded to Neutral from Buy at Mizuho
TMO Thermo Fisher
$490.36 /

-3.765 (-0.76%)

04/19/21 Credit Suisse
PPD downgraded to Neutral from Outperform at Credit Suisse
04/16/21 Deutsche Bank
PPD downgraded to Hold from Buy at Deutsche Bank
TMO Thermo Fisher
$490.36 /

-3.765 (-0.76%)

PPD PPD
$46.34 /

+0.12 (+0.26%)

  • 17
    Sep
TMO Thermo Fisher
$490.36 /

-3.765 (-0.76%)

PPD PPD
$46.34 /

+0.12 (+0.26%)

TMO Thermo Fisher
$490.36 /

-3.765 (-0.76%)

PPD PPD
$46.34 /

+0.12 (+0.26%)

Hot Stocks
PPD expands GMP lab in Ireland to bolster biopharmaceutical testing capabilities » 09:04
04/28/21
04/28
09:04
04/28/21
09:04
PPD

PPD

$46.34 /

+0.12 (+0.26%)

PPD is expanding its…

PPD is expanding its Athlone, Ireland, GMP laboratory, significantly increasing the size of its current facility and adding cell and gene therapy testing to the operation's portfolio of services. The expansion enhances PPD's ability to deliver global scientific and technical expertise to meet growing customer demand in Europe, the Middle East and Africa, and the Asia-Pacific region. By offering these services at its Athlone operation, PPD can provide clients in these locations with the same services already available in the U.S. through its Middleton, Wisconsin, GMP lab. "Our enlarged operations will enhance our capabilities in leading technologies related to biopharmaceutical testing and specialty testing for biologics and small molecules," said Christopher Fikry, M.D., executive vice president of PPD(R) Laboratories. "This expansion will enable PPD to provide customers with additional services aimed at reducing time to market for new drug products in important areas such as cell and gene therapies. We are thankful our expansion has been welcomed and supported by the Irish government and IDA Ireland, and we're confident these new developments will benefit our customers." The Athlone GMP lab provides fully integrated analytical services across all phases of pharmaceutical development and commercialization, helping clients fulfill regulatory requirements for release testing and qualified person services for clinical and marketed pharmaceuticals, including small and large molecules, inhaled products, and cell and gene therapies.

ShowHide Related Items >><<
PPD PPD
$46.34 /

+0.12 (+0.26%)

PPD PPD
$46.34 /

+0.12 (+0.26%)

04/20/21 Jefferies
PPD downgraded to Hold from Buy at Jefferies
04/19/21
Fly Intel: Top five analyst downgrades
04/19/21 Citi
PPD downgraded to Neutral from Buy at Citi
04/19/21 Mizuho
PPD downgraded to Neutral from Buy at Mizuho
PPD PPD
$46.34 /

+0.12 (+0.26%)

  • 17
    Sep
PPD PPD
$46.34 /

+0.12 (+0.26%)

PPD PPD
$46.34 /

+0.12 (+0.26%)

Hot Stocks
PPD not providing guidance » 16:16
04/27/21
04/27
16:16
04/27/21
16:16
PPD

PPD

$46.34 /

+0.12 (+0.26%)

The company states:…

The company states: "Due to the proposed merger with Thermo Fisher previously announced on April 15, 2021, which is subject to regulatory approvals in addition to the satisfaction of customary closing conditions, PPD will no longer be providing financial guidance."

ShowHide Related Items >><<
PPD PPD
$46.34 /

+0.12 (+0.26%)

PPD PPD
$46.34 /

+0.12 (+0.26%)

04/20/21 Jefferies
PPD downgraded to Hold from Buy at Jefferies
04/19/21
Fly Intel: Top five analyst downgrades
04/19/21 Citi
PPD downgraded to Neutral from Buy at Citi
04/19/21 Mizuho
PPD downgraded to Neutral from Buy at Mizuho
PPD PPD
$46.34 /

+0.12 (+0.26%)

  • 17
    Sep
PPD PPD
$46.34 /

+0.12 (+0.26%)

PPD PPD
$46.34 /

+0.12 (+0.26%)

Earnings
PPD reports Q1 adjusted EPS 35c, consensus 31c » 16:16
04/27/21
04/27
16:16
04/27/21
16:16
PPD

PPD

$46.34 /

+0.12 (+0.26%)

Reports Q1 revenue…

Reports Q1 revenue $1.38B, consensus $1.29B. "PPD's strong financial performance has continued," said David Simmons, PPD's chairman and CEO. "In addition, our more than 39% growth in net authorizations further underscores the demand for our differentiated capabilities across both the clinical development and labs services segments. Our talented colleagues have extended their track record of gaining share and delivering for customers. As we now anticipate joining Thermo Fisher Scientific later this year, the opportunities to bring meaningful innovation to market faster and more efficiently are as solid as ever."

ShowHide Related Items >><<
PPD PPD
$46.34 /

+0.12 (+0.26%)

PPD PPD
$46.34 /

+0.12 (+0.26%)

04/20/21 Jefferies
PPD downgraded to Hold from Buy at Jefferies
04/19/21
Fly Intel: Top five analyst downgrades
04/19/21 Citi
PPD downgraded to Neutral from Buy at Citi
04/19/21 Mizuho
PPD downgraded to Neutral from Buy at Mizuho
PPD PPD
$46.34 /

+0.12 (+0.26%)

  • 17
    Sep
PPD PPD
$46.34 /

+0.12 (+0.26%)

PPD PPD
$46.34 /

+0.12 (+0.26%)

Conference/Events
Society for Clinical Research Sites to hold a virtual summit Vertex Pharmaceuticals » 04:55
04/22/21
04/22
04:55
04/22/21
04:55
ABBV

AbbVie

$110.81 /

+1.78 (+1.63%)

, AMGN

Amgen

$258.70 /

-0.4 (-0.15%)

, AZN

AstraZeneca

$53.11 /

+0.84 (+1.61%)

, BAYRY

Bayer

$16.90 /

+0.55 (+3.36%)

, CPI

Capital Properties

$27.28 /

+ (+0.00%)

, GSK

GlaxoSmithKline

$38.25 /

+0.535 (+1.42%)

, ICLR

Icon

$210.78 /

+4.21 (+2.04%)

, IQV

Iqvia

$219.08 /

+2 (+0.92%)

, LLY

Eli Lilly

$191.00 /

+0.45 (+0.24%)

, MDT

Medtronic

$130.19 /

+1.9 (+1.48%)

, MEDP

Medpace

$188.28 /

+3.84 (+2.08%)

, MRK

Merck

$79.24 /

+0.67 (+0.85%)

, NOV

NOV Inc.

$13.08 /

+0.33 (+2.59%)

, NVS

Novartis

$88.67 /

+0.84 (+0.96%)

, PPD

PPD

$46.16 /

-0.095 (-0.21%)

, RHHBY

Roche

$43.19 /

+1.17 (+2.78%)

, SNY

Sanofi

$52.43 /

+0.44 (+0.85%)

, SYNH

Syneos Health

$87.89 /

+2.59 (+3.04%)

, VRTX

Vertex Pharmaceuticals

$219.79 /

-0.23 (-0.10%)

European Site Solutions…

European Site Solutions Virtual Summit will be held on April 20-22. Webcast Link

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$219.79 /

-0.23 (-0.10%)

SYNH Syneos Health
$87.89 /

+2.59 (+3.04%)

SNY Sanofi
$52.43 /

+0.44 (+0.85%)

RHHBY Roche
$43.19 /

+1.17 (+2.78%)

PPD PPD
$46.16 /

-0.095 (-0.21%)

NVS Novartis
$88.67 /

+0.84 (+0.96%)

NOV NOV Inc.
$13.08 /

+0.33 (+2.59%)

MRK Merck
$79.24 /

+0.67 (+0.85%)

MDT Medtronic
$130.19 /

+1.9 (+1.48%)

LLY Eli Lilly
$191.00 /

+0.45 (+0.24%)

IQV Iqvia
$219.08 /

+2 (+0.92%)

ICLR Icon
$210.78 /

+4.21 (+2.04%)

GSK GlaxoSmithKline
$38.25 /

+0.535 (+1.42%)

BAYRY Bayer
$16.90 /

+0.55 (+3.36%)

AZN AstraZeneca
$53.11 /

+0.84 (+1.61%)

AMGN Amgen
$258.70 /

-0.4 (-0.15%)

ABBV AbbVie
$110.81 /

+1.78 (+1.63%)

ABBV AbbVie
$110.81 /

+1.78 (+1.63%)

04/21/21 Citi
Citi sees 'material upside' for AbbVie, Bristol-Myers after Pfizer data
04/21/21 Citi
Citi opens '90-day positive catalyst' on AbbVie, reiterates Buy rating
04/06/21 RBC Capital
AbbVie transferred with an Outperform at RBC Capital
04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
AMGN Amgen
$258.70 /

-0.4 (-0.15%)

04/05/21 Oppenheimer
Amgen price target raised to $275 from $266 at Oppenheimer
04/01/21 Piper Sandler
Piper migraine survey bearish for Amgen, bullish for Biohaven
03/08/21 Guggenheim
Five Prime downgraded to Neutral from Buy at Guggenheim
03/05/21 Barclays
Amgen price target lowered to $230 from $242 at Barclays
AZN AstraZeneca
$53.11 /

+0.84 (+1.61%)

04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/12/21
Fly Intel: Top five analyst downgrades
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/12/21 Argus
AstraZeneca downgraded to Hold from Buy at Argus
BAYRY Bayer
$16.90 /

+0.55 (+3.36%)

03/19/21 Deutsche Bank
Bayer price target raised to EUR 66 from EUR 63 at Deutsche Bank
03/11/21 Societe Generale
Bayer price target lowered to EUR 59 from EUR 68 at Societe Generale
03/03/21 Berenberg
Bayer price target raised to EUR 68 from EUR 60 at Berenberg
03/02/21 Citi
Atara Biotherapeutics upgraded to Buy at Citi following 35% pullback
CPI Capital Properties
$27.28 /

+ (+0.00%)

GSK GlaxoSmithKline
$38.25 /

+0.535 (+1.42%)

04/20/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,550 GBp at Morgan Stanley
04/20/21 UBS
GlaxoSmithKline price target raised to 1,360 GBp from 1,320 GBp at UBS
04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
03/23/21
Fly Intel: Top five analyst downgrades
ICLR Icon
$210.78 /

+4.21 (+2.04%)

04/20/21 Baird
PRA Health downgraded to Neutral from Outperform at Baird
04/13/21 BofA
Icon resumed with a Neutral at BofA
04/01/21 Wells Fargo
Icon upgraded to Overweight from Equal Weight at Wells Fargo
04/01/21 Wells Fargo
Icon upgraded to Overweight from Equal Weight at Wells Fargo
IQV Iqvia
$219.08 /

+2 (+0.92%)

04/16/21
Fly Intel: Top five analyst upgrades
04/16/21 Stephens
Iqvia upgraded to Overweight with $250 price target at Stephens
04/16/21 Stephens
Iqvia upgraded to Overweight from Equal Weight at Stephens
04/09/21 Mizuho
Iqvia price target raised to $218 from $210 at Mizuho
LLY Eli Lilly
$191.00 /

+0.45 (+0.24%)

04/12/21 Benchmark
Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
03/24/21 BMO Capital
AbCellera price target lowered to $59 from $61 at BMO Capital
03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
MDT Medtronic
$130.19 /

+1.9 (+1.48%)

04/15/21 Atlantic Equities
Atlantic Equities starts Medtronic at Overweight
04/15/21 Atlantic Equities
Medtronic initiated with an Overweight at Atlantic Equities
04/05/21 Citi
Citi opens positive catalyst watches on four medical supply stocks
02/24/21 Cowen
Medtronic price target raised to $135 from $120 at Cowen
MEDP Medpace
$188.28 /

+3.84 (+2.08%)

02/17/21 Truist
Medpace price target raised to $180 from $135 at Truist
02/16/21 Credit Suisse
Medpace price target raised to $178 from $155 at Credit Suisse
10/02/20 Truist
Medpace upgraded to Buy from Hold at Truist
07/29/20 Truist
Medpace price target raised to $124 from $95 at SunTrust
MRK Merck
$79.24 /

+0.67 (+0.85%)

04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
04/08/21 Alliance Global Partners
Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
NOV NOV Inc.
$13.08 /

+0.33 (+2.59%)

01/21/21 Susquehanna
NOV Inc. price target lowered to $17 from $18 at Susquehanna
01/21/21 Wells Fargo
NOV Inc. upgraded to Overweight from Equal Weight at Wells Fargo
01/21/21 Wells Fargo
NOV Inc. upgraded to Overweight from Equal Weight at Wells Fargo
01/12/21 Citi
NOV Inc. upgraded to Buy from Neutral at Citi
NVS Novartis
$88.67 /

+0.84 (+0.96%)

04/19/21 UBS
Novartis price target raised to CHF 96 from CHF 95 at UBS
04/05/21 Morgan Stanley
Regenxbio AAV9 patent challenged by Passage Bio, says Morgan Stanley
03/23/21 Societe Generale
Novartis price target raised to CHF 107 from CHF 104 at Societe Generale
03/22/21 Bernstein
Novartis initiated with a Market Perform at Bernstein
PPD PPD
$46.16 /

-0.095 (-0.21%)

04/20/21 Jefferies
PPD downgraded to Hold from Buy at Jefferies
04/19/21
Fly Intel: Top five analyst downgrades
04/19/21 Citi
PPD downgraded to Neutral from Buy at Citi
04/19/21 Mizuho
PPD downgraded to Neutral from Buy at Mizuho
RHHBY Roche
$43.19 /

+1.17 (+2.78%)

03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
03/23/21 Truist
Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
SNY Sanofi
$52.43 /

+0.44 (+0.85%)

04/06/21 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
02/10/21 Morgan Stanley
Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
SYNH Syneos Health
$87.89 /

+2.59 (+3.04%)

03/02/21 Barclays
Syneos Health initiated with an Equal Weight at Barclays
03/02/21 Barclays
Syneos Health initiated with an Equal Weight at Barclays
02/22/21 Mizuho
Syneos Health price target raised to $87 from $72 at Mizuho
02/19/21 Citi
Syneos Health price target raised to $85 from $80 at Citi
VRTX Vertex Pharmaceuticals
$219.79 /

-0.23 (-0.10%)

04/21/21 Jefferies
Jefferies upgrades Crispr Therapeutics to Buy after Vertex deal renegotiated
04/21/21 Barclays
Crispr Therapeutics price target raised to $160 from $140 at Barclays
04/20/21 Chardan
Amended pact may show Vertex confidence in Crisper program, says Chardan
03/25/21 Citi
Citi likes share setup for Vertex Pharmaceuticals, adds to Focus List
VRTX Vertex Pharmaceuticals
$219.79 /

-0.23 (-0.10%)

SYNH Syneos Health
$87.89 /

+2.59 (+3.04%)

SNY Sanofi
$52.43 /

+0.44 (+0.85%)

RHHBY Roche
$43.19 /

+1.17 (+2.78%)

PPD PPD
$46.16 /

-0.095 (-0.21%)

NVS Novartis
$88.67 /

+0.84 (+0.96%)

NOV NOV Inc.
$13.08 /

+0.33 (+2.59%)

MRK Merck
$79.24 /

+0.67 (+0.85%)

MEDP Medpace
$188.28 /

+3.84 (+2.08%)

MDT Medtronic
$130.19 /

+1.9 (+1.48%)

LLY Eli Lilly
$191.00 /

+0.45 (+0.24%)

IQV Iqvia
$219.08 /

+2 (+0.92%)

ICLR Icon
$210.78 /

+4.21 (+2.04%)

GSK GlaxoSmithKline
$38.25 /

+0.535 (+1.42%)

BAYRY Bayer
$16.90 /

+0.55 (+3.36%)

AZN AstraZeneca
$53.11 /

+0.84 (+1.61%)

AMGN Amgen
$258.70 /

-0.4 (-0.15%)

ABBV AbbVie
$110.81 /

+1.78 (+1.63%)

  • 01
    Mar
  • 02
    Dec
  • 16
    Sep
  • 17
    Sep
VRTX Vertex Pharmaceuticals
$219.79 /

-0.23 (-0.10%)

SNY Sanofi
$52.43 /

+0.44 (+0.85%)

RHHBY Roche
$43.19 /

+1.17 (+2.78%)

PPD PPD
$46.16 /

-0.095 (-0.21%)

NVS Novartis
$88.67 /

+0.84 (+0.96%)

MRK Merck
$79.24 /

+0.67 (+0.85%)

LLY Eli Lilly
$191.00 /

+0.45 (+0.24%)

ICLR Icon
$210.78 /

+4.21 (+2.04%)

GSK GlaxoSmithKline
$38.25 /

+0.535 (+1.42%)

BAYRY Bayer
$16.90 /

+0.55 (+3.36%)

AZN AstraZeneca
$53.11 /

+0.84 (+1.61%)

AMGN Amgen
$258.70 /

-0.4 (-0.15%)

ABBV AbbVie
$110.81 /

+1.78 (+1.63%)

VRTX Vertex Pharmaceuticals
$219.79 /

-0.23 (-0.10%)

SNY Sanofi
$52.43 /

+0.44 (+0.85%)

RHHBY Roche
$43.19 /

+1.17 (+2.78%)

PPD PPD
$46.16 /

-0.095 (-0.21%)

NVS Novartis
$88.67 /

+0.84 (+0.96%)

NOV NOV Inc.
$13.08 /

+0.33 (+2.59%)

MRK Merck
$79.24 /

+0.67 (+0.85%)

LLY Eli Lilly
$191.00 /

+0.45 (+0.24%)

IQV Iqvia
$219.08 /

+2 (+0.92%)

ICLR Icon
$210.78 /

+4.21 (+2.04%)

GSK GlaxoSmithKline
$38.25 /

+0.535 (+1.42%)

BAYRY Bayer
$16.90 /

+0.55 (+3.36%)

AZN AstraZeneca
$53.11 /

+0.84 (+1.61%)

AMGN Amgen
$258.70 /

-0.4 (-0.15%)

ABBV AbbVie
$110.81 /

+1.78 (+1.63%)

VRTX Vertex Pharmaceuticals
$219.79 /

-0.23 (-0.10%)

NOV NOV Inc.
$13.08 /

+0.33 (+2.59%)

MRK Merck
$79.24 /

+0.67 (+0.85%)

MDT Medtronic
$130.19 /

+1.9 (+1.48%)

LLY Eli Lilly
$191.00 /

+0.45 (+0.24%)

IQV Iqvia
$219.08 /

+2 (+0.92%)

GSK GlaxoSmithKline
$38.25 /

+0.535 (+1.42%)

AZN AstraZeneca
$53.11 /

+0.84 (+1.61%)

AMGN Amgen
$258.70 /

-0.4 (-0.15%)

ABBV AbbVie
$110.81 /

+1.78 (+1.63%)

Conference/Events
Society for Clinical Research Sites to hold a virtual summit Vertex Pharmaceuticals » 09:55
04/21/21
04/21
09:55
04/21/21
09:55
ABBV

AbbVie

$110.77 /

+1.74 (+1.60%)

, AMGN

Amgen

$259.77 /

+0.67 (+0.26%)

, AZN

AstraZeneca

$52.80 /

+0.53 (+1.01%)

, BAYRY

Bayer

$16.35 /

-0.24 (-1.45%)

, CPI

Capital Properties

$27.28 /

+ (+0.00%)

, GSK

GlaxoSmithKline

$38.06 /

+0.35 (+0.93%)

, ICLR

Icon

$206.49 /

-0.08 (-0.04%)

, IQV

Iqvia

$215.69 /

-1.39 (-0.64%)

, LLY

Eli Lilly

$191.76 /

+1.21 (+0.64%)

, MDT

Medtronic

$128.91 /

+0.62 (+0.48%)

, MEDP

Medpace

$184.51 /

+0.07 (+0.04%)

, MRK

Merck

$78.85 /

+0.28 (+0.36%)

, NOV

NOV Inc.

$12.66 /

-0.09 (-0.71%)

, NVS

Novartis

$88.47 /

+0.64 (+0.73%)

, PPD

PPD

$46.28 /

+0.03 (+0.06%)

, RHHBY

Roche

$42.02 /

-0.26 (-0.61%)

, SNY

Sanofi

$52.31 /

+0.32 (+0.62%)

, SYNH

Syneos Health

$85.29 /

-0.01 (-0.01%)

, VRTX

Vertex Pharmaceuticals

$219.75 /

-0.27 (-0.12%)

European Site Solutions…

European Site Solutions Virtual Summit will be held on April 20-22. Webcast Link

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$219.75 /

-0.27 (-0.12%)

SYNH Syneos Health
$85.29 /

-0.01 (-0.01%)

SNY Sanofi
$52.31 /

+0.32 (+0.62%)

RHHBY Roche
$42.02 /

-0.26 (-0.61%)

PPD PPD
$46.28 /

+0.03 (+0.06%)

NVS Novartis
$88.47 /

+0.64 (+0.73%)

NOV NOV Inc.
$12.66 /

-0.09 (-0.71%)

MRK Merck
$78.85 /

+0.28 (+0.36%)

MDT Medtronic
$128.91 /

+0.62 (+0.48%)

LLY Eli Lilly
$191.76 /

+1.21 (+0.64%)

IQV Iqvia
$215.69 /

-1.39 (-0.64%)

ICLR Icon
$206.49 /

-0.08 (-0.04%)

GSK GlaxoSmithKline
$38.06 /

+0.35 (+0.93%)

BAYRY Bayer
$16.35 /

-0.24 (-1.45%)

AZN AstraZeneca
$52.80 /

+0.53 (+1.01%)

AMGN Amgen
$259.77 /

+0.67 (+0.26%)

ABBV AbbVie
$110.77 /

+1.74 (+1.60%)

ABBV AbbVie
$110.77 /

+1.74 (+1.60%)

04/21/21 Citi
Citi sees 'material upside' for AbbVie, Bristol-Myers after Pfizer data
04/21/21 Citi
Citi opens '90-day positive catalyst' on AbbVie, reiterates Buy rating
04/06/21 RBC Capital
AbbVie transferred with an Outperform at RBC Capital
04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
AMGN Amgen
$259.77 /

+0.67 (+0.26%)

04/05/21 Oppenheimer
Amgen price target raised to $275 from $266 at Oppenheimer
04/01/21 Piper Sandler
Piper migraine survey bearish for Amgen, bullish for Biohaven
03/08/21 Guggenheim
Five Prime downgraded to Neutral from Buy at Guggenheim
03/05/21 Barclays
Amgen price target lowered to $230 from $242 at Barclays
AZN AstraZeneca
$52.80 /

+0.53 (+1.01%)

04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/12/21
Fly Intel: Top five analyst downgrades
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/12/21 Argus
AstraZeneca downgraded to Hold from Buy at Argus
BAYRY Bayer
$16.35 /

-0.24 (-1.45%)

03/19/21 Deutsche Bank
Bayer price target raised to EUR 66 from EUR 63 at Deutsche Bank
03/11/21 Societe Generale
Bayer price target lowered to EUR 59 from EUR 68 at Societe Generale
03/03/21 Berenberg
Bayer price target raised to EUR 68 from EUR 60 at Berenberg
03/02/21 Citi
Atara Biotherapeutics upgraded to Buy at Citi following 35% pullback
CPI Capital Properties
$27.28 /

+ (+0.00%)

GSK GlaxoSmithKline
$38.06 /

+0.35 (+0.93%)

04/20/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,550 GBp at Morgan Stanley
04/20/21 UBS
GlaxoSmithKline price target raised to 1,360 GBp from 1,320 GBp at UBS
04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
03/23/21
Fly Intel: Top five analyst downgrades
ICLR Icon
$206.49 /

-0.08 (-0.04%)

04/20/21 Baird
PRA Health downgraded to Neutral from Outperform at Baird
04/13/21 BofA
Icon resumed with a Neutral at BofA
04/01/21 Wells Fargo
Icon upgraded to Overweight from Equal Weight at Wells Fargo
04/01/21 Wells Fargo
Icon upgraded to Overweight from Equal Weight at Wells Fargo
IQV Iqvia
$215.69 /

-1.39 (-0.64%)

04/16/21
Fly Intel: Top five analyst upgrades
04/16/21 Stephens
Iqvia upgraded to Overweight with $250 price target at Stephens
04/16/21 Stephens
Iqvia upgraded to Overweight from Equal Weight at Stephens
04/09/21 Mizuho
Iqvia price target raised to $218 from $210 at Mizuho
LLY Eli Lilly
$191.76 /

+1.21 (+0.64%)

04/12/21 Benchmark
Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
03/24/21 BMO Capital
AbCellera price target lowered to $59 from $61 at BMO Capital
03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
MDT Medtronic
$128.91 /

+0.62 (+0.48%)

04/15/21 Atlantic Equities
Atlantic Equities starts Medtronic at Overweight
04/15/21 Atlantic Equities
Medtronic initiated with an Overweight at Atlantic Equities
04/05/21 Citi
Citi opens positive catalyst watches on four medical supply stocks
02/24/21 Cowen
Medtronic price target raised to $135 from $120 at Cowen
MEDP Medpace
$184.51 /

+0.07 (+0.04%)

02/17/21 Truist
Medpace price target raised to $180 from $135 at Truist
02/16/21 Credit Suisse
Medpace price target raised to $178 from $155 at Credit Suisse
10/02/20 Truist
Medpace upgraded to Buy from Hold at Truist
07/29/20 Truist
Medpace price target raised to $124 from $95 at SunTrust
MRK Merck
$78.85 /

+0.28 (+0.36%)

04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
04/08/21 Alliance Global Partners
Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
NOV NOV Inc.
$12.66 /

-0.09 (-0.71%)

01/21/21 Susquehanna
NOV Inc. price target lowered to $17 from $18 at Susquehanna
01/21/21 Wells Fargo
NOV Inc. upgraded to Overweight from Equal Weight at Wells Fargo
01/21/21 Wells Fargo
NOV Inc. upgraded to Overweight from Equal Weight at Wells Fargo
01/12/21 Citi
NOV Inc. upgraded to Buy from Neutral at Citi
NVS Novartis
$88.47 /

+0.64 (+0.73%)

04/19/21 UBS
Novartis price target raised to CHF 96 from CHF 95 at UBS
04/05/21 Morgan Stanley
Regenxbio AAV9 patent challenged by Passage Bio, says Morgan Stanley
03/23/21 Societe Generale
Novartis price target raised to CHF 107 from CHF 104 at Societe Generale
03/22/21 Bernstein
Novartis initiated with a Market Perform at Bernstein
PPD PPD
$46.28 /

+0.03 (+0.06%)

04/20/21 Jefferies
PPD downgraded to Hold from Buy at Jefferies
04/19/21
Fly Intel: Top five analyst downgrades
04/19/21 Citi
PPD downgraded to Neutral from Buy at Citi
04/19/21 Mizuho
PPD downgraded to Neutral from Buy at Mizuho
RHHBY Roche
$42.02 /

-0.26 (-0.61%)

03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
03/23/21 Truist
Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
SNY Sanofi
$52.31 /

+0.32 (+0.62%)

04/06/21 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
02/10/21 Morgan Stanley
Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
SYNH Syneos Health
$85.29 /

-0.01 (-0.01%)

03/02/21 Barclays
Syneos Health initiated with an Equal Weight at Barclays
03/02/21 Barclays
Syneos Health initiated with an Equal Weight at Barclays
02/22/21 Mizuho
Syneos Health price target raised to $87 from $72 at Mizuho
02/19/21 Citi
Syneos Health price target raised to $85 from $80 at Citi
VRTX Vertex Pharmaceuticals
$219.75 /

-0.27 (-0.12%)

04/21/21 Jefferies
Jefferies upgrades Crispr Therapeutics to Buy after Vertex deal renegotiated
04/21/21 Barclays
Crispr Therapeutics price target raised to $160 from $140 at Barclays
04/20/21 Chardan
Amended pact may show Vertex confidence in Crisper program, says Chardan
03/25/21 Citi
Citi likes share setup for Vertex Pharmaceuticals, adds to Focus List
VRTX Vertex Pharmaceuticals
$219.75 /

-0.27 (-0.12%)

SYNH Syneos Health
$85.29 /

-0.01 (-0.01%)

SNY Sanofi
$52.31 /

+0.32 (+0.62%)

RHHBY Roche
$42.02 /

-0.26 (-0.61%)

PPD PPD
$46.28 /

+0.03 (+0.06%)

NVS Novartis
$88.47 /

+0.64 (+0.73%)

NOV NOV Inc.
$12.66 /

-0.09 (-0.71%)

MRK Merck
$78.85 /

+0.28 (+0.36%)

MEDP Medpace
$184.51 /

+0.07 (+0.04%)

MDT Medtronic
$128.91 /

+0.62 (+0.48%)

LLY Eli Lilly
$191.76 /

+1.21 (+0.64%)

IQV Iqvia
$215.69 /

-1.39 (-0.64%)

ICLR Icon
$206.49 /

-0.08 (-0.04%)

GSK GlaxoSmithKline
$38.06 /

+0.35 (+0.93%)

BAYRY Bayer
$16.35 /

-0.24 (-1.45%)

AZN AstraZeneca
$52.80 /

+0.53 (+1.01%)

AMGN Amgen
$259.77 /

+0.67 (+0.26%)

ABBV AbbVie
$110.77 /

+1.74 (+1.60%)

  • 01
    Mar
  • 02
    Dec
  • 16
    Sep
  • 17
    Sep
VRTX Vertex Pharmaceuticals
$219.75 /

-0.27 (-0.12%)

SNY Sanofi
$52.31 /

+0.32 (+0.62%)

RHHBY Roche
$42.02 /

-0.26 (-0.61%)

PPD PPD
$46.28 /

+0.03 (+0.06%)

NVS Novartis
$88.47 /

+0.64 (+0.73%)

MRK Merck
$78.85 /

+0.28 (+0.36%)

LLY Eli Lilly
$191.76 /

+1.21 (+0.64%)

ICLR Icon
$206.49 /

-0.08 (-0.04%)

GSK GlaxoSmithKline
$38.06 /

+0.35 (+0.93%)

BAYRY Bayer
$16.35 /

-0.24 (-1.45%)

AZN AstraZeneca
$52.80 /

+0.53 (+1.01%)

AMGN Amgen
$259.77 /

+0.67 (+0.26%)

ABBV AbbVie
$110.77 /

+1.74 (+1.60%)

VRTX Vertex Pharmaceuticals
$219.75 /

-0.27 (-0.12%)

SNY Sanofi
$52.31 /

+0.32 (+0.62%)

RHHBY Roche
$42.02 /

-0.26 (-0.61%)

PPD PPD
$46.28 /

+0.03 (+0.06%)

NVS Novartis
$88.47 /

+0.64 (+0.73%)

NOV NOV Inc.
$12.66 /

-0.09 (-0.71%)

MRK Merck
$78.85 /

+0.28 (+0.36%)

LLY Eli Lilly
$191.76 /

+1.21 (+0.64%)

IQV Iqvia
$215.69 /

-1.39 (-0.64%)

ICLR Icon
$206.49 /

-0.08 (-0.04%)

GSK GlaxoSmithKline
$38.06 /

+0.35 (+0.93%)

BAYRY Bayer
$16.35 /

-0.24 (-1.45%)

AZN AstraZeneca
$52.80 /

+0.53 (+1.01%)

AMGN Amgen
$259.77 /

+0.67 (+0.26%)

ABBV AbbVie
$110.77 /

+1.74 (+1.60%)

VRTX Vertex Pharmaceuticals
$219.75 /

-0.27 (-0.12%)

NOV NOV Inc.
$12.66 /

-0.09 (-0.71%)

MRK Merck
$78.85 /

+0.28 (+0.36%)

MDT Medtronic
$128.91 /

+0.62 (+0.48%)

LLY Eli Lilly
$191.76 /

+1.21 (+0.64%)

IQV Iqvia
$215.69 /

-1.39 (-0.64%)

GSK GlaxoSmithKline
$38.06 /

+0.35 (+0.93%)

AZN AstraZeneca
$52.80 /

+0.53 (+1.01%)

AMGN Amgen
$259.77 /

+0.67 (+0.26%)

ABBV AbbVie
$110.77 /

+1.74 (+1.60%)

Downgrade
PPD downgraded to Hold from Buy at Jefferies » 08:30
04/20/21
04/20
08:30
04/20/21
08:30
PPD

PPD

$46.20 /

-0.1 (-0.22%)

Jefferies analyst David…

Jefferies analyst David Windley downgraded PPD (PPD) to Hold from Buy with a price target of $47.50, up from $43, following news that Thermo Fisher (TMO) has agreed to acquire the company for $47.50 per share in cash.

ShowHide Related Items >><<
PPD PPD
$46.20 /

-0.1 (-0.22%)

PPD PPD
$46.20 /

-0.1 (-0.22%)

04/19/21
Fly Intel: Top five analyst downgrades
04/19/21 Citi
PPD downgraded to Neutral from Buy at Citi
04/19/21 Mizuho
PPD downgraded to Neutral from Buy at Mizuho
04/19/21 Credit Suisse
PPD downgraded to Neutral from Outperform at Credit Suisse
PPD PPD
$46.20 /

-0.1 (-0.22%)

  • 17
    Sep
PPD PPD
$46.20 /

-0.1 (-0.22%)

PPD PPD
$46.20 /

-0.1 (-0.22%)

Downgrade
Fly Intel: Top five analyst downgrades » 09:53
04/19/21
04/19
09:53
04/19/21
09:53
DFS

Discover

$100.03 /

-2.26 (-2.21%)

, CHD

Church & Dwight

$86.22 /

-1.82 (-2.07%)

, PPD

PPD

$46.30 /

+ (+0.00%)

, SKX

Skechers

$44.59 /

-0.24 (-0.54%)

, PGR

Progressive

$98.30 /

-0.49 (-0.50%)

Catch up on today's…

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Discover (DFS) downgraded to Market Perform from Outperform at BMO Capital with analyst James Fotheringham citing "exclusively" valuation for the downgrade. 2. Church & Dwight (CHD) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Dara Mohsenian saying the stock looks "priced to perfection" in an environment that is not favorable to U.S. household and personal care names. 3. PPD (PPD) downgraded to Neutral from Outperform at Credit Suisse and downgraded to Neutral from Buy at Mizuho and Citi. 4. Skechers (SKX) downgraded to Neutral from Buy at Monness Crespi with analyst Jim Chartier saying while he thinks trends in the U.S. and China were likely strong in Q1, lockdowns in Europe were likely a sales headwind and near-term visibility remains limited given some EU lockdowns continuing into April and a slower than expected vaccine rollout across most of Europe. 5. Progressive (PGR) downgraded to Outperform from Strong Buy at Raymond James with analyst C. Gregory Peters saying as the benefits from Covid begin to lapse, the analyst expects accident frequency to increase and lower margins. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
SKX Skechers
$44.59 /

-0.24 (-0.54%)

PPD PPD
$46.30 /

+ (+0.00%)

PGR Progressive
$98.30 /

-0.49 (-0.50%)

DFS Discover
$100.03 /

-2.26 (-2.21%)

CHD Church & Dwight
$86.22 /

-1.82 (-2.07%)

DFS Discover
$100.03 /

-2.26 (-2.21%)

04/18/21 BMO Capital
Discover downgraded to Market Perform from Outperform at BMO Capital
04/16/21 Piper Sandler
Discover price target raised to $103 from $97 at Piper Sandler
04/08/21 Piper Sandler
Discover price target raised to $97 from $94 at Piper Sandler
03/17/21 Wedbush
LendingClub price target raised to $20.50 from $14 at Wedbush
CHD Church & Dwight
$86.22 /

-1.82 (-2.07%)

04/19/21 Morgan Stanley
Church & Dwight downgraded to Underweight from Equal Weight at Morgan Stanley
04/16/21 JPMorgan
Church & Dwight price target raised to $80 from $79 at JPMorgan
12/07/20 Wells Fargo
Church & Dwight initiated with an Equal Weight at Wells Fargo
08/03/20 Truist
Church & Dwight price target raised to $105 from $90 at Truist
PPD PPD
$46.30 /

+ (+0.00%)

04/19/21 Citi
PPD downgraded to Neutral from Buy at Citi
04/19/21 Mizuho
PPD downgraded to Neutral from Buy at Mizuho
04/19/21 Credit Suisse
PPD downgraded to Neutral from Outperform at Credit Suisse
04/16/21 Deutsche Bank
PPD downgraded to Hold from Buy at Deutsche Bank
SKX Skechers
$44.59 /

-0.24 (-0.54%)

04/19/21 Monness Crespi
Skechers downgraded to Neutral on EU lockdown headwinds at Monness Crespi
04/19/21 Monness Crespi
Skechers downgraded to Neutral from Buy at Monness Crespi
04/19/21 Deutsche Bank
Skechers price target raised to $49 from $41 at Deutsche Bank
01/22/21 Williams Capital
Skechers initiated with a Hold at Williams Trading
PGR Progressive
$98.30 /

-0.49 (-0.50%)

04/19/21 Raymond James
Progressive downgraded to Outperform from Strong Buy at Raymond James
03/18/21 Edward Jones
Progressive upgraded to Buy from Hold at Edward Jones
03/09/21 BofA
BofA starts Root at Underperform with $9 price target
02/01/21 Deutsche Bank
Progressive price target lowered to $105 from $108 at Deutsche Bank
SKX Skechers
$44.59 /

-0.24 (-0.54%)

PPD PPD
$46.30 /

+ (+0.00%)

PGR Progressive
$98.30 /

-0.49 (-0.50%)

DFS Discover
$100.03 /

-2.26 (-2.21%)

CHD Church & Dwight
$86.22 /

-1.82 (-2.07%)

  • 17
    Sep
PPD PPD
$46.30 /

+ (+0.00%)

SKX Skechers
$44.59 /

-0.24 (-0.54%)

PPD PPD
$46.30 /

+ (+0.00%)

DFS Discover
$100.03 /

-2.26 (-2.21%)

CHD Church & Dwight
$86.22 /

-1.82 (-2.07%)

SKX Skechers
$44.59 /

-0.24 (-0.54%)

PGR Progressive
$98.30 /

-0.49 (-0.50%)

DFS Discover
$100.03 /

-2.26 (-2.21%)

Downgrade
PPD downgraded to Neutral from Buy at Citi » 06:47
04/19/21
04/19
06:47
04/19/21
06:47
PPD

PPD

$46.30 /

+0.49 (+1.07%)

, TMO

Thermo Fisher

$492.86 /

-1.505 (-0.30%)

Citi analyst Patrick…

Citi analyst Patrick Donnelly downgraded PPD (PPD) to Neutral from Buy with a $47.50 price target to reflect the pending takeover by Thermo Fisher (TMO). The analyst anticipates the deal will be approved and does not expect any higher takeout offers from other bidders.

ShowHide Related Items >><<
TMO Thermo Fisher
$492.86 /

-1.505 (-0.30%)

PPD PPD
$46.30 /

+0.49 (+1.07%)

PPD PPD
$46.30 /

+0.49 (+1.07%)

04/19/21 Mizuho
PPD downgraded to Neutral from Buy at Mizuho
04/19/21 Credit Suisse
PPD downgraded to Neutral from Outperform at Credit Suisse
04/16/21 Deutsche Bank
PPD downgraded to Hold from Buy at Deutsche Bank
04/16/21 William Blair
PPD downgraded to Market Perform from Outperform at William Blair
TMO Thermo Fisher
$492.86 /

-1.505 (-0.30%)

TMO Thermo Fisher
$492.86 /

-1.505 (-0.30%)

PPD PPD
$46.30 /

+0.49 (+1.07%)

  • 17
    Sep
TMO Thermo Fisher
$492.86 /

-1.505 (-0.30%)

PPD PPD
$46.30 /

+0.49 (+1.07%)

TMO Thermo Fisher
$492.86 /

-1.505 (-0.30%)

PPD PPD
$46.30 /

+0.49 (+1.07%)

Downgrade
PPD downgraded to Neutral from Buy at Mizuho » 06:38
04/19/21
04/19
06:38
04/19/21
06:38
PPD

PPD

$46.30 /

+0.49 (+1.07%)

, TMO

Thermo Fisher

$492.86 /

-1.505 (-0.30%)

Mizuho analyst Ann Hynes…

Mizuho analyst Ann Hynes downgraded PPD (PPD) to Neutral from Buy with a price target of $47.50, up from $38, to reflect the announced acquisition by Thermo Fisher (TMO). The analyst does not expect any others bidders "given the rich purchase multiple."

ShowHide Related Items >><<
TMO Thermo Fisher
$492.86 /

-1.505 (-0.30%)

PPD PPD
$46.30 /

+0.49 (+1.07%)

PPD PPD
$46.30 /

+0.49 (+1.07%)

04/19/21 Credit Suisse
PPD downgraded to Neutral from Outperform at Credit Suisse
04/16/21 Deutsche Bank
PPD downgraded to Hold from Buy at Deutsche Bank
04/16/21 William Blair
PPD downgraded to Market Perform from Outperform at William Blair
04/16/21 Evercore ISI
Thermo Fisher price target raised to $540 from $525 at Evercore ISI
TMO Thermo Fisher
$492.86 /

-1.505 (-0.30%)

TMO Thermo Fisher
$492.86 /

-1.505 (-0.30%)

PPD PPD
$46.30 /

+0.49 (+1.07%)

  • 17
    Sep
TMO Thermo Fisher
$492.86 /

-1.505 (-0.30%)

PPD PPD
$46.30 /

+0.49 (+1.07%)

TMO Thermo Fisher
$492.86 /

-1.505 (-0.30%)

PPD PPD
$46.30 /

+0.49 (+1.07%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.